Dipexium Pharmaceuticals Llc (DPRX) 9.28 $DPRX
Dipexium Pharmaceuticals Closes Initial Public Offering
PR Newswire - Tue Mar 18, 10:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ

PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the closing of its initial public offering of 3,162,500 shares of its common stock at a public offering price of $12.00 per share.
Dipexium Pharmaceuticals Prices Initial Public Offering of Common Stock
PR Newswire - Thu Mar 13, 7:00AM CDT
Dipexium Pharmaceuticals, Inc. (NASDAQ

PRX), a late stage biopharmaceutical company developing Locilex(TM) (pexiganan acetate cream 1%), a proposed treatment for mild infections of diabetic foot ulcers, today announced the pricing of its initial public offering of 2,750,000 shares of its common stock at a public offering price of $12.00 per share. All shares of common stock are being offered by the company. In addition, Dipexium has granted the underwriters a 30-day option to purchase up to an additional 412,500 shares of common stock at the same price to cover over-allotments, if any.